- Home
- UTL vs IOVA Comparison
UTL vs IOVA Comparison
Compare UTL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTL
- IOVA
- Stock Information
- Founded
- UTL 1984
- IOVA 2007
- Country
- UTL United States
- IOVA United States
- Employees
- UTL N/A
- IOVA N/A
- Industry
- UTL Power Generation
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UTL Utilities
- IOVA Health Care
- Exchange
- UTL Nasdaq
- IOVA Nasdaq
- Market Cap
- UTL 842.0M
- IOVA 771.4M
- IPO Year
- UTL N/A
- IOVA N/A
- Fundamental
- Price
- UTL $51.87
- IOVA $3.13
- Analyst Decision
- UTL Hold
- IOVA Buy
- Analyst Count
- UTL 1
- IOVA 10
- Target Price
- UTL $55.00
- IOVA $12.22
- AVG Volume (30 Days)
- UTL 68.5K
- IOVA 23.9M
- Earning Date
- UTL 08-04-2025
- IOVA 08-07-2025
- Dividend Yield
- UTL 3.47%
- IOVA N/A
- EPS Growth
- UTL N/A
- IOVA N/A
- EPS
- UTL 2.93
- IOVA N/A
- Revenue
- UTL $486,900,000.00
- IOVA $212,679,000.00
- Revenue This Year
- UTL $13.90
- IOVA $86.62
- Revenue Next Year
- UTL $7.89
- IOVA $69.95
- P/E Ratio
- UTL $17.72
- IOVA N/A
- Revenue Growth
- UTL N/A
- IOVA 11070.12
- 52 Week Low
- UTL $50.81
- IOVA $1.64
- 52 Week High
- UTL $63.52
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- UTL 47.37
- IOVA 62.71
- Support Level
- UTL $50.81
- IOVA $1.70
- Resistance Level
- UTL $53.37
- IOVA $4.33
- Average True Range (ATR)
- UTL 0.84
- IOVA 0.35
- MACD
- UTL 0.13
- IOVA 0.17
- Stochastic Oscillator
- UTL 41.41
- IOVA 54.55
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.